References
- 1. Pan E, Prados MD. Primary neoplasm of the central nervous system. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, editors. Holland-Frei Cancer Medicine 6th ed. Ontario: BC Decker; 2003. p. 879-900.
- 2. Frosch MP, Antony DC, Girolami UD. The central nervous system. In: Kumar V, Abbas AK, Fauston N, editors. Robbins & Cotran Pathologic Basis of Disease 7th ed. Pennsylvania: Elsevier Inc; 2005. p. 1401-14.
- 3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol. 2007; 114:97-109.10.1007/s00401-007-0243-4
- 4. Mckeever PE. Insights about brain tumors gained through immunohistochemistry and in situ hybridization of nuclear and phenotypic markers. J Histochem Cytochem. 1998; 46:585-94.10.1177/002215549804600504
- 5. Chen D, Chen F, Yang X, Lu X, Zu Z, Pan J, et al. Identification of prohibitin as a potential biomarker for colorectal carcinoma base on proteomics technology. Int J oncol. 2010; 37:355-65.
- 6. Wang J, Dong Y, Wang X, Ma H, Sheng Z, Li G, et al. Expression of EphA1 in gastric carcinoma is associated with metastasis and survival. Oncol Rep. 2010; 24: 1577-84.
- 7. Ahn SH, Sawada H, RO JY, Nicolson GL. Differential expression of annexin I in human mammary ductal epithelial cells in normal and benign and malignant breast tissue. Clin Exp Metastasis. 1997; 15:151-6.10.1023/A:1018452810915
- 8. Chen G, Gharib TG, Huang CC, Thomas DG, Shedden KA, Taylor JM, et al. Proteomics analysis of lung adenocarcinoma: identification of highly expressed set of protein in tumors. Clin Cancer Res. 2002; 7: 2298-305.
- 9. De Bont JM, den Boer ML, Kros JM, Pasier MM, Reddingius RE, Smitt PA, et al. Identification of novel biomarkers in pediatric primitive neuroectodermal tumor and ependymomas by proteome-wide analysis. J Neuropathol Exp Neurol. 2007; 66:505-16.10.1097/01.jnen.0000240475.35414.c3
- 10. Park CK, Jung JH, Park SH, Jung HW, Cho BK. Multifarious proteomics signatures and regional heterogeneity in glioblastomas. J Neurooncol. 2009; 94:31-9.10.1007/s11060-009-9805-8
- 11. Schittenhelm J, Trautmann K, Tabatabai G, Hermann C, Meyermann R, Beschorner R. Comparative analysis of annexin-1 in neuroepithelial tumors show altered expression with the grade of malignancy but is not associated with survival. Mod Pathol. 2009; 22: 1600-11.10.1038/modpathol.2009.132
- 12. Johnso MD, Kamso-Pratt J, Pepsinsky RB, Whetsel WO Jr. Lipocortin in central and peripheral nervous system glial tumor. Hum Pathol. 1989; 20:772-6.10.1016/0046-8177(89)90071-3
- 13. Zhang Y, Li Q, Zhu F, Cui J, Li K, Li Q, et al. Subcellular localization of APMCF I and its biological significance of expression pattern in normal and malignant human tissue. J Exp Clin Cancer Res. 2009; 28:111-6.10.1186/1756-9966-28-111
- 14. Lim LH, Perraiz S. Annexin 1: The new face of an old molecule. FASEB J. 2007; 21:968-75.10.1096/fj.06-7464rev
- 15. Allderidge LC, Bryant CE. Annexin 1 regulates cell proliferation by disruption of cell morphology and inhibition of cyclin D1 expression through sustained activation of ERK1/ 2 MAPK signal. Exp Cell Res. 2003; 290:93-107.
- 16. D’ Acquisto F, Merghani A, Lecona E, Rosignoli G, Raza K, Buckley CD, et al. Annexin-1 modulates T-cell activation and differentiation. Blood. 2007; 109: 1090-102.
- 17. Solito E, de Coupade C, Canaider S, Goulding NJ, Perretti M. Transfection of Annexin 1 in monocytic cell produces a high degree of spontaneous and stimulate apoptosis associated with caspase-3 activation. Br J Pharmacol. 2001; 133:217-28.10.1038/sj.bjp.0704054
- 18. Falini B, Tiacci E, Liso A, Basso K, Sabattini E, Pacini R, et al. Simple diagnostic assay for hairy cell leukemia by immunohistochemical detection of Annexin A1 (ANXA1). Lancet. 2004; 363:1869-70.10.1016/S0140-6736(04)16356-3
- 19. Masaki T, Tokuda M, Ohnishi M, Watanabe S, Fujimura T, Miyamoto K, et al. Enhance expression of protein kinase substrate annexin in human hepatocellular carcinoma. Hepatology. 1996; 24:72-81.
- 20. Sinha P, Hutter G, Kottgen E, Dietel M, Schadendorf D, Larg H. Increased expression of annexin l and thioredoxin detect by two-dimensional gel electrophoresis of drug resistant human stomach cancer cells. J Biochem Biophys Methods. 1998; 37: 105-16.10.1016/S0165-022X(98)00020-7
- 21. Bai XF, Ni XG, Zhao P, Lui SM, Wang HX, Gou B, et al. Over-expression of Annexin1 in pancreatic cancer and its clinical significance. World J Gastroenterol. 2004; 10:1466-70.10.3748/wjg.v10.i10.1466
- 22. Xia SH, Hu LP, Hu H, Ying WT, Xu X, Cai Y, et al. Three isoform of Annexin l are preferentially expressed in normal esophageal epithelial but down regulate in esophageal squamous cell carcinomas. Oncogene. 2002; 21:6641-8.10.1038/sj.onc.1205818
- 23. Kang JS, Calvo BF, Maygarden SJ, Caskey LS, Mohler JL, Ornstien DK. Dysregulation of annexin 1 protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. Clin cancer Res. 2002; 8:117-23.
- 24. Garcia Pedrero JM, Fernandez MP, Morgan RO, Herrero ZA, Gonzailez MV, Suazez NC, et al. Annexin A1 down-regulation in head and neck cancer is associated with epithelial differentiation status. Am J Pahtol. 2004; 164:73-9.
- 25. Vishwanatha JK, Salazer E, Gopalakrishnan VK. Absence of annexin l expression in B-cell non- Hodgkin’s lymphomas and cell lines. BMC cancer. 2004; 4:8-16.10.1186/1471-2407-4-8
- 26. Solito E, Mcarther S, Christian H, Gavin F, Buckingham JC, Gillines GE. Annexin A1 in the brain - undiscovered roles? Trends Phamacol Sci. 2008; 29:135-42.
- 27. Johnson MD, Gray ME, Pepinsky RB, Stahlman MT. Lipocortin-1 immunoreactivity in human pituitary gland. J Histochem Cytochem. 1990; 38:1814-45.10.1177/38.12.2147709
- 28. Probst-Cousin S, Kowolik D, Kuchelmeister K, Kayser C, Neundorfer B, Heuss D. Expression of Annexin-1 in multiple sclerosis plaques. Neuropathol Appl Neurobiol. 2002; 28:292-300.10.1046/j.1365-2990.2002.00396.x
- 29. Liu Y, Fallow L, Lashuel HA, Lui Z, Lansbury PT Jr.
- The UCH-L1 gene encodes two opposing enzimatic activites that affct alpha-Synuclein degradation and Parkinson’s disease susceptibility. Cell. 2002; 111: 209 -18.
- 30. Rolen U, Freda E, Xie J, Pfirrmann T, Frisan T, Masucci MG. The ubiquitin c-terminal hydrolase UCH-L1 regulates B-cell proliferation and integrin activation. J cell Mol Med. 2009; 13:1666-78.10.1111/j.1582-4934.2008.00501.x
- 31. Gavioli R, Frisan T, Vertuani S, Bornkamm GW, Masucci MG. c-myc overexpression activation alternative pathways for intracellular proteolysis in lymphoma cells. Nat Cell Biol. 2001; 3:283-8.10.1038/35060076
- 32. Tezel E, Hibi k, Nakasha T, Nakao A. PGP 9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res. 2006; 12:4764 -7.
- 33. Takase T, Hibi K, Yamazaki T, Nakayama H, Taguchi M, Kasia Y, et al. PGP9.5 Overexpression in esophageal squamous cell carcinoma. Hepatogastroenterology. 2003; 50:1278-80.
- 34. Okochi-Takada E, Nakazawa K, Wakabayashi M, Mori A, Ichimura S, Yasugi T, et al. Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J cancer. 2006; 119:1338-44.
- 35. Takumaru Y, Yamashita K, Osada M, Nomoto S, Sun D, Xiao Y, et al. Inverse correlation between cyclin A1 Hypermethylation and P53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res. 2004; 64:5982-7.
- 36. Yu J, Tao Q, Cheung KF, Jin H, Poon FF, Wang X, et al. Epigenetic identification of ubiquitin carboxylterminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumor. Hepatology. 2008; 48:508-18.10.1002/hep.22343
- 37. Day IN, Thomson RJ. UCHL1 (PGP 9.5): neuronal biomarker and ubiquitin system protein. Neurobiology. 2010; 90:327-62.
- 38. Sesuie R, Wada K. The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int. 2007; 51:105-11.